Aclaris Therapeutics to release clinical trial results April 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
- Hertz cuts guidance, announces notes and stock offerings, shares sink
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
April 27, 2026 4:45 PM EDTWAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026.
Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss... More
